Original Research

Psychiatric uses of topiramate: What is the current evidence?

Pierre M Joubert
South African Journal of Psychiatry | Vol 14, No 2 | a157 | DOI: https://doi.org/10.4102/sajpsychiatry.v14i2.157 | © 2008 Pierre M Joubert | This work is licensed under CC Attribution 4.0
Submitted: 15 September 2008 | Published: 01 June 2008

About the author(s)

Pierre M Joubert, Department of Psychiatry, School of Medicine, Faculty of Health Sciences, University of Pretoria and Weskoppies Hospital, Pretoria

Full Text:

PDF (128KB)

Abstract

Topiramate enhances gamma-amino-butyric acid effects, has anti- glutaminergic effects, and is a state-dependent sodium channel blocker. 1 It is registered as an adjunctive treatment for epilepsy but is not registered for psychiatric indications. Nevertheless, it may be useful beyond its initial indication, considering the promising literature on which I report below. However, much more research evidence is needed to establish sufficient scientific justification for prescribing it routinely for psychiatric purposes.

Keywords

No related keywords in the metadata.

Metrics

Total abstract views: 2953
Total article views: 1909


Crossref Citations

No related citations found.